Blutungsrisiko unter Antidepressiva mit Hemmung der Serotoninwiederaufnahme

R. Zeiss; B. J. Connemann; C. Schönfeldt-Lecuona; M. Gahr

doi:10.1055/s-0038-1675698

Nervenheilkunde, Table of Contents

Nervenheilkunde 2018; 37(11): 799-802
DOI: 10.1055/s-0038-1675698

Universitätsklinikum Ulm

Georg Thieme Verlag KG Stuttgart · New York

Blutungsrisiko unter Antidepressiva mit Hemmung der Serotoninwiederaufnahme

Risk of bleeding related to antidepressants with serotonin reuptake inhibition

Authors

R. Zeiss

¹Universitätsklinikum Ulm, Klinik für Psychiatrie und Psychotherapie III, Ulm
B. J. Connemann

¹Universitätsklinikum Ulm, Klinik für Psychiatrie und Psychotherapie III, Ulm
C. Schönfeldt-Lecuona

¹Universitätsklinikum Ulm, Klinik für Psychiatrie und Psychotherapie III, Ulm
M. Gahr

¹Universitätsklinikum Ulm, Klinik für Psychiatrie und Psychotherapie III, Ulm

Abstract

Zusammenfassung

Gegenstand und Ziel: Blutungsereignisse unter Therapie mit Antidepressiva, die die Serotoninwiederaufnahme hemmen (SRI), sind in den Fokus der klinischen und wissenschaftlichen Aufmerksamkeit gerückt. In der vorliegenden Übersichtsarbeit wird ein Überblick über den Kenntnisstand zu SRI-assoziierten Blutungen, insbesondere in Hinblick auf möglichen Pathomechanismen und verschiedene Blutungslokalisationen gegeben. Material und Methoden: Es wurde eine narrative Übersichtsarbeit erstellt. Die Literaturrecherche wurde in der bibliografischen Datenbank MEDLINE durchgeführt. Ergebnisse: Zahlreiche Studien deuten darauf hin, dass SRI, insbesondere SSRI, das Risiko für obere gastrointestinale Blutungen erhöhen können; eine Komedikation mit NSAID oder Thrombozytenaggregationshemmern erhöht dieses Risiko deutlich. Die Datenlage zu anderen Blutungslokalisationen ist für sichere Bewertungen gegenwärtig unzureichend. Es gibt Hinweise auf einen positiven Zusammenhang zwischen der Affinität eines SRI zum Serotonintransporter (5-HTT) und dem assoziierten Blutungsrisiko. Schlussfolgerungen und klinische Relevanz: Ein erhöhtes Risiko für Blutungen (insbesondere obere gastrointestinale Blutungen) durch SRI sowie eine Erhöhung dieses Risikos durch NSAID und/oder Thrombozytenaggregationshemmer sollte bei der Verordnung von SRI, insbesondere von SRI mit hoher Affinität zum 5-HTT (z. B. SSRI), beachtet werden.

Summary

Objective: Hemorrhages associated with the use of antidepressants that inhibit serotonin reuptake (SRI) have become a focus of attention in clinical practice and science. This review article provides an overview of the currently available data regarding bleeding events associated with SRI with a focus on pathophysiology and different sites of bleeding. Material and methods: A narrative review article was created. Literature search was performed in the bibliographic database of MEDLINE. Results: Numerous studies have demonstrated an increased risk for upper gastrointestinal bleeding related to SRI, particularly, SSRI; comedication with NSAID or anti-platelet agents increases this risk remarkably. The currently available data does not allow reliable evaluation regarding other sites of bleeding. There is indication for an association between the affinity of an SRI to the serotonin transporter (5-HTT) and the associated risk of bleeding. Conclusion: An increased bleeding risk of bleeding (particularly upper gastrointestinal bleedings) associated with the use of SRI and an additionally increased risk under comedication with NSAID and/or antiplatelet agents should be taken into account, especially regarding SRI with high affinity to the 5-HTT (e. g., SSRI).

Schlüsselwörter

Antidepressiva - Psychopharmaka - Serotoninwiederaufnahmehemmer

Keywords

Antidepressant drugs - psychotropic drugs - serotonin reuptake inhibitor

Full Text

References

Literatur
1 de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interactions with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795-803.
2 de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol 2000; 50: 43-7.
3 de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-1109.
4 Abdel OMESalam. Fluoxetine and sertraline stimulate gastric acid secretion via a vagal pathway in anaesthetised rats. Pharmacol Res 2004; 50: 309-316.
5 Akoudad S, Aarts N, Noordam R, Ikram MA, Tiemeier H, Hofman A, Stricker BH, Vernooij MW, Visser LE. Antidepressant Use Is Associated With an Increased Risk of Developing Microbleeds. Stroke 2015; 47: 251-254.
6 Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a metaanalysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36.
7 Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: A review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565-1575.
8 Andrade C, Sharma E. Serotonin Reuptake Inhibitors and Risk of Abnormal Bleeding. Psychiatr Clin North Am 2016; 39: 413-426.
9 Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadi GI. Risk of upper gastrointestinal bleeding with selective serotononin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review an metaanalysis. Am J Gastroenterol 2014; 109: 811-819.
10 Auerbach AD, Vittinghoff E, Maselli J, Pekow PS, Young JQ, Lindenauer PK. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes in surgery. JAMA Intern Med 2013; 173: 1075-1081.
11 Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, García LARodríguez, Christensen K, Gaist D. Selective serotonin reuptake inhibitors and the risk of stroke: a populationbased case-control study. Stroke 2002; 33: 1465-73.
12 Basile FV, Basile AR, Basile VV. Use of Selective Serotonin Reuptake Inhibitors Antidepressants and Bleeding Risk in Breast Cosmetic Surgery. Aesthetic Plast Surg 2013; 37: 561-566.
13 Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network metaanalysis. Lancet 2018; 391: 1357-1366.
14 Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59-64.
15 DGPPN: S3-Leitlinie / Nationale VersorgungsLeitlinie Unipolare Depression Langfassung. Ärztliches Zent. für Qual. der Medizin Published Online First. 2015 doi:10.6101/AZQ/000266.
16 Douglas I, Smeeth L, Irvine D. The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study. Br J Clin Pharmacol 2011; 71: 116-120.
17 Douros A, Ades M, Renoux C. Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review. CNS Drugs 2018; 32: 321-334.
18 Gahr M, Zeiss R, Lang D, Connemann BJ, Hiemke C, Muche R, Freudenmann RW, Schönfeldt-Lecuona C. Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. Psychiatry Res 2015; 229: 257-263.
19 Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a metaanalysis. Neurology 2012; 79: 1862-1865.
20 Hoirisch-Clapauch S, Nardi AE, Gris JC, Brenner B. Are the antiplatelet and profibrinolytic properties of selective serotonin-reuptake inhibitors relevant to their brain effects?. Thromb Res 2014; 134: 11-16.
21 Jonnakuty C, Gragnoli C. What do we know about serotonin?. J Cell Physiol 2008; 217: 301-306.
22 Li N, Wallén NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 08: 517-523.
23 Mahdanian AA, Looper KJ, Bacon SL, Mesurolle B, Meterissian SH, Rej S. Serotonergic antidepressants and increased bleeding risk in patients undergoing breast biopsy. Ther Adv Psychopharmacol 2015; 05: 332-338.
24 Meijer WEE, Heerdink ER, Nolen WA, Herings RMC, Leufkens HGM, Egberts ACG. Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by Antidepressants. Arch Intern Med 2004; 164: 2367.
25 Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane database Syst Rev. 2006: CD003491
26 Movig KLL, Janssen MWHE, de Waal JMalefijt, Kabel PJ, Leufkens HGM, Egberts ACG. Relationship of Serotonergic Antidepressants and Need for Blood Transfusion in Orthopedic Surgical Patients. Arch Intern Med 2003; 163: 2354.
27 National Institute for Heath and Care Excellence. National Institute for Health and Care Excellence Depression in adults: treatment and management. Published Online First: 2018 https://www.nice.org.uk/guidance/gid-cgwave0725/documents/fullguideline-updated.
28 Raote I, Bhattacharya A, Panicker MM. Serotonin 2A (5-HT2A) Receptor Function: Ligand-Dependent Mechanisms and Pathways CRC Press/ Taylor & Francis; 2007 http://www.ncbi.nlm.nih.gov/pubmed/21204452 (accessed 9 Sep2018).
29 Renoux C, Vahey S, Dell’Aniello S, Boivin J-F. Association of Selective Serotonin Reuptake Inhibitors With the Risk for Spontaneous Intracranial Hemorrhage. JAMA Neurol 2017; 74: 173.
30 Roose SP, Rutherford BR. Selective Serotonin Reuptake Inhibitors and Operative Bleeding Risk: A Review of the Literature. J Clin Psychopharmacol 2016; 36: 704-709.
31 Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168: 180-185.
32 Schelleman H, Brensinger CM, Bilker WB, Hennessy S. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One 2011; 06: e21447.
33 Schutte HJ, Jansen S, Schafroth MU, Goslings JC, van der Velde N, de Rooij SEJA. SSRIs Increase Risk of Blood Transfusion in Patients Admitted for Hip Surgery. PLoS One 2014; 09: e95906.
34 Ulrich DPSchwabe. Arzneiverordnungs-Report 2016. 1st ed. Berlin: Springer Verlag; 2016
35 van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323: 655-8.
36 Williams JW, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J, Williams Jr. JW, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 2000; 132: 743-756.
37 Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a metaanalysis. Int J Geriatr Psychiatry 2004; 19: 754-62.
38 Wu C-S, Wang S-C, Cheng Y-C, Gau SS-F. Association of Cerebrovascular Events With Antidepressant Use: A Case-Crossover Study. Am J Psychiatry 2011; 168: 511-521.
39 Yuan Y, Tsoi K, Hunt RH. Selective Serotonin Reuptake Inhibitors and Risk of Upper GI Bleeding: Confusion or Confounding?. Am J Med 2006; 119: 719-727.